Antibodies to Myelin P0 and Ceramide Perpetuate Neuropathy in Long Standing Treated Leprosy Patients

Raju, Ravikiran M.; Devi, S. Karuna; Mehervani, C.; Kumar, Amit; Meena, A K; Reddy, P.P.; Pranay, Penaguluru; Jain, Suman; Archelos-Gracia, J. J.; Suneetha, Sujai; Suneetha, Lavanya M.

doi:10.1007/s11064-010-0397-7

Cited by 10 publications

(7 citation statements)

References 40 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The maximum fold increase was observed in Ceramide antibody followed by TNF-α, followed by S100 antibody and PGL-1 (Table 1 and Figure 2) suggesting the combination of these four serological markers could be a choice to understand reaction and their relationship to nerve damage. In addition, to the above mentioned four serological markers other inflammatory and autoimmune markers which have a fold increase such as Interferon-inducible protein-10 (IP-10) [22] and Myelin P0 [23-25] should be explored for understanding the nerve damage.…”

Section: Discussionmentioning

confidence: 99%

Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B

Raju¹,

Suneetha²,

Jadhav

et al. 2014

Lipids Health Dis

Self Cite

View full text Add to dashboard Cite

BackgroundCorticosteroids have been extensively used in the treatment of immunological reactions and neuritis in leprosy. The present study evaluates the serological response to steroid treatment in leprosy reactions and neuritis.MethodsSeven serological markers [TNF-α, antibodies to Phenolic glycolipid-1 (PGL-1 IgM and IgG), Lipoarabinomannan (LAM IgG1 and IgG3), C2-Ceramide and S100 B] were analyzed longitudinally in 72 leprosy patients before, during and after the reaction. At the onset of reaction these patients received a standard course of prednisolone. The levels of the above markers were measured by Enzyme linked immunosorbent assay (ELISA) and compared with the individuals own value in the month prior to the reaction and presented as percentage increase.ResultsOne month before the reaction individuals showed a varying increase in the level of different markers such as TNF-α (53%) and antibodies to Ceramide (53%), followed by to PGL-1 (51%), S100B (50%) and LAM (26%). The increase was significantly associated with clinical finding of nerve pain, tenderness and new nerve function impairment. After one month prednisolone therapy, there was a fall in the levels [TNF-α (60%), C2-Ceramide (54%), S100B (67%), PGL-1(47%) and LAM (52%)] with each marker responding differently to steroid.ConclusionReactions in leprosy are inflammatory processes wherein a rise in set of serological markers can be detected a month before the clinical onset of reaction, some of which remain elevated during their action and steroid treatment induces a variable fall in the levels, and this forms the basis for a variable individual response to steroid therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B

Raju¹,

Suneetha²,

Jadhav

et al. 2014

Lipids Health Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is known that in long-standing treated leprosy patients, the persistent bacterial antigen can incite nerve autoantibodies that can perpetuate neuropathy. [ 23 ] A study from Brazil observed that the impairment status worsened in 40% of patients 10 years after RFT. [ 24 ] Studies have also shown that the cumulative probability of worsening of the physical disability grade of persons treated and declared cured of leprosy increases with time.…”

Section: Discussionmentioning

confidence: 99%

Dermlep Study Part 3

Rao

Suneetha

Rathod

et al. 2022

Indian Dermatology Online Journal

Self Cite

View full text Add to dashboard Cite

Introduction: Presently the leprosy program has no defined surveillance protocols for patients who complete the fixed duration multidrug therapy and are released from treatment (RFT). Hence, the information about the post-RFT events in these patients is sparse and qualitative and quantitative data regarding their health care requirements is missing. During the DermLep survey carried out by the Indian Association of Dermatologists,Venereologists and Leprologists (IADVL), a number of patients presented to dermatologists during the post RFT period for a variety of symptoms. This paper analyses the events in these patients during the post RFT period. Results: Out of a total of 3701 leprosy patients who presented to 201 dermatologists across India during the DermLep survey, 708 (26.2%) were in the post RFT period (488 males; 220 females). Of these, 21% were PB and 79% MB patients as per their treatment records. Majority were in the age group of 31-59 years (55.5%); however, a significant proportion of them (20.7%) were elderly (>60 years). Majority of the patients (45.5%) presented within the first year of RFT with variable symptoms; 28% were between 1-5 years, 5.5% between 5-10 years; and 11.0% presented more than 10 years after RFT. Most common presenting complaint being persistent skin lesions as perceived by patients in 21.2%, followed by neuritis in 14.5%; trophic ulcers in 13.8%; deformities in 67 (11.8%); lepra reactions in 66 (11.6%); and recurrence of original symptoms in 6.7%. Conclusion: The DermLep Surve y highlights the importance of ‘post RFT’ patients as an important subset of leprosy patients who visit dermatologists for various health related issues. The most common complaints in this subset were active/persistent skin lesions, lepra reactions and neuritis. In these patients, who are a sub-group of ‘persons affected with leprosy’ the disease related issues can persist for many years post RFT. Hence, it is important to provide services in the programme to monitor and manage these complications for the prevention of impairments, disability and the related social issues.

show abstract

“…It has been observed that nerve function impairment (NFI) once acquired worsens with time, especially in MB patients[ 34 ] and neuritis/new deformities continue to develop in certain forms of leprosy even after RFT. [ 35 36 ]…”

Section: Discussionmentioning

confidence: 99%

The dermlep study I: results of prospective nation-wide survey of the number & Profile of leprosy patients seen by dermatologists in India

Rao

Rathod

Suneetha³

et al. 2020

Indian Dermatol Online J

Self Cite

View full text Add to dashboard Cite

Antibodies to Myelin P0 and Ceramide Perpetuate Neuropathy in Long Standing Treated Leprosy Patients

Cited by 10 publications

References 40 publications

Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B

Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B

Dermlep Study Part 3

The dermlep study I: results of prospective nation-wide survey of the number & Profile of leprosy patients seen by dermatologists in India

Contact Info

Product

Resources

About